Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).

Abstract

Recently, we have introduced [tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772, FFC24) as a new lanthanum compound which has promising anticancer properties in vivo and in vitro. Aim of this study was to investigate the impact of ABC transporter-mediated multidrug resistance (MDR) on the anticancer activity of KP772. Here, we demonstrate that all MDR cell models investigated, overexpressing ABCB1 (P-glycoprotein), ABCC1 (multidrug resistance protein 1), or ABCG2 (breast cancer resistance protein) either due to drug selection or gene transfection, were significantly hypersensitive against KP772. Using ABCB1-overexpressing KBC-1 cells as MDR model, KP772 hypersensitivity was demonstrated to be based on stronger apoptosis induction and/or cell cycle arrest at unaltered cellular drug accumulation. KP772 did neither stimulate ABCB1 ATPase activity nor alter rhodamine 123 accumulation arguing against a direct interaction with ABCB1. Accordingly, several drug resistance modulators did not sensitize but rather protect MDR cells against KP772-induced cytotoxicity. Moreover, long-term KP772 treatment of KBC-1 cells at subtoxic concentrations led within 20 passages to a complete loss of drug resistance based on blocked MDR1 gene expression. When exposing parental KB-3-1 cells to subtoxic, stepwise increasing KP772 concentrations, we observed, in contrast to several other metallo-drugs, no acquisition of KP772 resistance. Summarizing, our data demonstrate that KP772 is hyperactive in MDR cells and might have chemosensitizing properties by blocking ABCB1 expression. Together with the disability of tumor cells to acquire KP772 resistance, our data suggest that KP772 should be especially active against notoriously drug-resistant tumor types and as second line treatment after standard chemotherapy failure.

• Authors: P Heffeter, M A Jakupec, W Körner, P Chiba, C Pirker, R Dornetshuber, L Elbling, H Sutterlüty, M Micksche, B K Keppler, W Berger
• Journal: Biochemical pharmacology (Biochem Pharmacol) Vol. 73 Issue 12 Pg. 1873-86 (Jun 15 2007) ISSN: 0006-2952 [Print] England
• PMID: 17445775 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• ABCB1 protein, human
• ABCG2 protein, human
• ATP Binding Cassette Transporter, Subfamily B
• ATP Binding Cassette Transporter, Subfamily B, Member 1
• ATP Binding Cassette Transporter, Subfamily G, Member 2
• ATP-Binding Cassette Transporters
• Antineoplastic Agents
• Formazans
• Neoplasm Proteins
• Organic Anion Transporters
• Organometallic Compounds
• Phenanthrolines
• Tetrazolium Salts
• tris(1,10-phenanthroline)lanthanum(III)
• MTT formazan
• Lanthanum

Topics

• ATP Binding Cassette Transporter, Subfamily B
• ATP Binding Cassette Transporter, Subfamily B, Member 1 (metabolism)
• ATP Binding Cassette Transporter, Subfamily G, Member 2
• ATP-Binding Cassette Transporters (metabolism)
• Adenocarcinoma (drug therapy)
• Antineoplastic Agents (chemistry, pharmacology, therapeutic use)
• Apoptosis (drug effects)
• Breast Neoplasms (drug therapy)
• Carcinoma, Small Cell (drug therapy)
• Cell Cycle (drug effects)
• Cell Line, Tumor
• Dose-Response Relationship, Drug
• Drug Resistance, Multiple
• Drug Resistance, Neoplasm
• Formazans (metabolism)
• HL-60 Cells
• Humans
• Lanthanum (chemistry, pharmacology, therapeutic use)
• Lung Neoplasms (drug therapy)
• Molecular Structure
• Neoplasm Proteins (metabolism)
• Organic Anion Transporters (metabolism)
• Organometallic Compounds (chemistry, pharmacology, therapeutic use)
• Phenanthrolines (chemistry, pharmacology, therapeutic use)
• Sensitivity and Specificity
• Tetrazolium Salts (metabolism)